Challenges in the Design of Reliable Immuno-Oncology Mouse Models to Inform Drug Development
2017; Future Science Ltd; Volume: 9; Issue: 12 Linguagem: Inglês
10.4155/fmc-2017-0027
ISSN1756-8927
AutoresGiada Mondanelli, Claudia Volpi, Ciriana Orabona, Ursula Grohmann,
Tópico(s)Cancer, Stress, Anesthesia, and Immune Response
ResumoFuture Medicinal ChemistryVol. 9, No. 12 CommentaryChallenges in the design of reliable immuno-oncology mouse models to inform drug developmentGiada Mondanelli, Claudia Volpi, Ciriana Orabona & Ursula GrohmannGiada Mondanelli Department of Experimental Medicine, University of Perugia, P. le Gambuli n.1, 06132 Perugia, Italy, Claudia Volpi Department of Experimental Medicine, University of Perugia, P. le Gambuli n.1, 06132 Perugia, Italy, Ciriana Orabona Department of Experimental Medicine, University of Perugia, P. le Gambuli n.1, 06132 Perugia, Italy & Ursula Grohmann*Author for correspondence: E-mail Address: ursula.grohmann@unipg.it Department of Experimental Medicine, University of Perugia, P. le Gambuli n.1, 06132 Perugia, ItalyPublished Online:3 Aug 2017https://doi.org/10.4155/fmc-2017-0027AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: arginine metabolismcheckpoint inhibitorsdendritic cellimmune regulationTGF-βtryptophan metabolismReferences1 Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumor antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat. Rev. Cancer 14(2), 135–146 (2014).Crossref, Medline, CAS, Google Scholar2 Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148 (2016).Crossref, Medline, CAS, Google Scholar3 Zak KM, Kitel R, Przetocka S et al. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure 23(12), 2341–2348 (2015).Crossref, Medline, CAS, Google Scholar4 Chang HN, Liu BY, Qi YK et al. Blocking of the PD-1/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy. Angew. Chem. Int. Ed. Engl. 54(40), 11760–11764 (2015).Crossref, Medline, CAS, Google Scholar5 Zak KM, Grudnik P, Guzik K et al. Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1). Oncotarget 7(21), 30323–30335 (2016).Crossref, Medline, Google Scholar6 Powles T, Eder JP, Fine GD et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515(7528), 558–562 (2014).Crossref, Medline, CAS, Google Scholar7 Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int. Immunol. 28(8), 383–391 (2016).Crossref, Medline, CAS, Google Scholar8 Yusuke Oku, Tareyanagi C, Takaya S et al. Multimodal effects of small molecule ROCK and LIMK inhibitors on mitosis, and their implication as anti-leukemia agents. PLoS ONE 9(3), e92402 (2014).Crossref, Medline, Google Scholar9 Kastl J, Braun J, Prestel A, Möller HM, Huhn T, Mayer TU. Mad2 inhibitor-1 (M2I-1): a small molecule protein-protein interaction inhibitor targeting the mitotic spindle assembly checkpoint. ACS Chem. Biol. 10(7), 1661–1666 (2015).Crossref, Medline, CAS, Google Scholar10 Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162–174 (2009).Crossref, Medline, CAS, Google Scholar11 Brandacher G, Perathoner A, Ladurner R et al. Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12(4), 1144–1151 (2006).Crossref, Medline, CAS, Google Scholar12 Mondanelli G, Bianchi R, Pallotta MT et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells. Immunity 46(2), 233–244 (2017).Crossref, Medline, CAS, Google Scholar13 Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2, 3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210(7), 1389–1402 (2013).Crossref, Medline, CAS, Google Scholar14 Dounay AB, Tuttle JB, Verhoest PR. Challenges and opportunities in the discovery of new therapeutics targeting the kynurenine pathway. J. Med. Chem. 58(22), 8762–8782 (2015).Crossref, Medline, CAS, Google Scholar15 Katz LH, Li Y, Chen JS et al. Targeting TGF-beta signaling in cancer. Expert Opin. Ther. Targets 17(7), 743–760 (2013).Crossref, Medline, CAS, Google Scholar16 Gould SE, Junttila MR, de Sauvage FJ. Translational value of mouse models in oncology drug development. Nat. Med. 21(5), 431–439 (2015).Crossref, Medline, CAS, Google Scholar17 Morton JJ, Bird G, Refaeli Y, Jimeno A. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap. Cancer Res. 76(21), 6153–6158 (2016).Crossref, Medline, CAS, Google Scholar18 Couzin-Frankel J. Hope in a mouse. Science 346(6205), 28–29 (2014).Crossref, Medline, CAS, Google Scholar19 Calon A, Lonardo E, Berenguer-Llergo A et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47(4), 320–329 (2015).Crossref, Medline, CAS, Google Scholar20 Xie L, Maeda J, Kumata K et al. Development of 1-N-11C methyl-l- and -d-tryptophan for pharmacokinetic imaging of the immune checkpoint inhibitor 1-methyl-tryptophan. Sci. Rep. 5, 16417 (2015).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited BySAR study of small molecule inhibitors of the programmed cell death‐1/programmed cell death‐ligand 1 interaction23 September 2021 | Chemical Biology & Drug Design, Vol. 98, No. 5Combination of Bacterial‐Photothermal Therapy with an Anti‐PD‐1 Peptide Depot for Enhanced Immunity against Advanced Cancer22 October 2019 | Advanced Functional Materials, Vol. 30, No. 1The Characteristics of PD-L1 Inhibitors, from Peptides to Small Molecules20 May 2019 | Molecules, Vol. 24, No. 10Immunotherapy… a pursuit race to tomorrow's medicinesAntonio Macchiarulo3 August 2017 | Future Medicinal Chemistry, Vol. 9, No. 12 Vol. 9, No. 12 Follow us on social media for the latest updates Metrics Downloaded 151 times History Published online 3 August 2017 Published in print August 2017 Information© 2017 Future Science LtdKeywordsarginine metabolismcheckpoint inhibitorsdendritic cellimmune regulationTGF-βtryptophan metabolismFinancial & competing interests disclosureThe European Research Council (338954-DIDO to U Grohmann) and the Italian Ministry of Education, Universities and Research (PRIN2012–2012S47X27 to C Orabona) supported this work. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)